OS Therapies (OSTX) stock
OSTX's Quality Score rose 2 points on Fri, Oct 2, to 0. Made a higher high and a higher low (2 chart checks started).
Follow OSTX's news. Pro members can get an alert when OS Therapies files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for OSTX, and how long its cash lasts
From OS Therapies’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Cash runway
The company says its cash lasts into 2027 (8-K, Jul 2).
Dilution on the horizon
- Shelf registration (S-3, filed Aug 8, 2025)
- At-the-market share sales program (424B5, filed Aug 21, 2026)
Insiders
No open-market buys or sales by its officers or directors in their filings of the last year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 25 daysINOInovio Pharmaceuticals
INOINO-3107
- In 36 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 48 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why OSTX scores -1
PoorChoppy, 3 of 14 checks firingWhat the Quality Score means
- +3Chart checks 3 of 14 firing right now, one point each
- −1Long-term trend below a rising 200-day average, down over one year, down over two years
- Size subtracts
- Profit subtracts
- Volatility subtracts
- Cash flow subtracts
- News adds
Big story
What's next
Wed Oct 7: BioJapan 2026Industry event · date confirmed.
Expected to report Mon Nov 16, before the open
1 more date ahead for Pro members: the conference
What would turn OSTX's score around: 7 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
OSTX has 3 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1442.6
- MACD (12, 26, 9)Below signal
- 50-day average$1.65
- 200-day average$1.58
- ADX 1411.0
- Support$1.47
- Resistance$1.64
- Bollinger Bands (20, 2)Inside
- Volume0.6x
How OSTX ranks in Biotech
OSTX is #159 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
ORKAOpen for its score
PBLSOpen for its score
PBYIOpen for its score
OSTX3/14-1
When does OSTX report earnings, and what happens after?
Expected to report Mon Nov 16, before the open (in 42 days). Not yet confirmed by the company.
About OS Therapies
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of OSTX's score, with the points and the reason
- All 14 checks on OSTX and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on OSTX
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.